Eligible patients will be randomly assigned to either the treatment group ( bolus infusion of 2,000 g sodium selenite immediately prior to surgery , followed by an additional dosage of 2,000 g at ICU admission , and a further daily supplementation of 1,000 g up to 10 days or ICU discharge ) or to the control group ( placebo administration at the same time points ) .